

## Sepsis patients with first and second-hit infections show different outcomes depending on the causative organism

Matthew Morgan<sup>1, 2\*</sup>, Tamas Szakmany<sup>1, 3\*</sup>, Sarah G. Power<sup>4</sup>, Patrick Olaniyi<sup>5</sup>, Kathy Rowan<sup>4</sup>, Judith E. Hall<sup>1</sup>, Matthias Eberl<sup>1, 6</sup>

<sup>1</sup>Division of Infection & Immunity, School of Medicine, Cardiff University, United Kingdom, <sup>2</sup>Directorate of Critical Care, Cardiff and Vale University Health Board, United Kingdom, <sup>3</sup>ACT Directorate, Cwm Taf University Health Board, United Kingdom, <sup>4</sup>Intensive Care National Audit & Research Centre, United Kingdom, <sup>5</sup>Institute of Life Science, Swansea University, United Kingdom, <sup>6</sup>Systems Immunity Research Institute, Cardiff University, United Kingdom

*Submitted to Journal:*  
Frontiers in Microbiology

*Specialty Section:*  
Infectious Diseases

*ISSN:*  
1664-302X

*Article type:*  
Original Research Article

*Received on:*  
12 Oct 2015

*Accepted on:*  
08 Feb 2016

*Provisional PDF published on:*  
08 Feb 2016

*Frontiers website link:*  
[www.frontiersin.org](http://www.frontiersin.org)

*Citation:*  
Morgan M, Szakmany T, Power SG, Olaniyi P, Rowan K, Hall JE and Eberl M(2016) Sepsis patients with first and second-hit infections show different outcomes depending on the causative organism. *Front. Microbiol.* 7:207. doi:10.3389/fmicb.2016.00207

*Copyright statement:*  
© 2016 Morgan, Szakmany, Power, Olaniyi, Rowan, Hall and Eberl. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

This Provisional PDF corresponds to the article as it appeared upon acceptance, after peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

Provisional

1           **Sepsis patients with first and second-hit infections show**  
2           **different outcomes depending on the causative organism**

3  
4   Matt P. Morgan (PhD),<sup>1,2</sup> Tamas Szakmany (PhD),<sup>1,3\*</sup> Sarah Power (MSc),<sup>4</sup> Patrick  
5   Olaniyi (BSc),<sup>5</sup> Judith E. Hall (MD),<sup>1</sup> Kathy Rowan (PhD),<sup>4</sup> Matthias Eberl (PhD)<sup>1,6</sup>

6  
7   <sup>1</sup> *Division of Infection & Immunity, School of Medicine, Cardiff University, Heath Park,*  
8   *Cardiff CF14 4XN, UK;*

9   <sup>2</sup> *Directorate of Critical Care, Cardiff & Vale University Health Board, Heath Park,*  
10   *Cardiff, CF14 4XW, UK*

11   <sup>3</sup> *ACT Directorate, Cwm Taf University Health Board, Llantrisant, CF72 8XR, UK*

12   <sup>4</sup> *Intensive Care National Audit & Research Centre (ICNARC), Napier House, 24 High*  
13   *Holborn, London WC1V 6AZ, UK;*

14   <sup>5</sup> *Institute of Life Science, College of Medicine, Swansea University, Singleton Park,*  
15   *Swansea, SA2 8PP, UK*

16   <sup>6</sup> *Systems Immunity Research Institute, Cardiff University, Heath Park, Cardiff CF14*  
17   *4XN, UK*

18  
19   Correspondence to: **Dr Tamas Szakmany**, *Department of Anaesthesia, Intensive Care*  
20   *and Pain Medicine, Division of Infection & Immunity, School of Medicine, Cardiff*  
21   *University, Heath Park, Cardiff CF14 4XN, UK. e-mail: Szakmany1@cardiff.ac.uk; Dr*  
22   **Matt Morgan**, *Directorate of Critical Care, Cardiff & Vale University Health Board,*  
23   *Heath Park, Cardiff, CF14 4XW, UK. e-mail: MorganMP@cardiff.ac.uk*

26 **Abstract**

27 **Objective.** With improving rates of initial survival in severe sepsis, second-hit  
28 infections that occur following resolution of the primary insult carry an increasing  
29 burden of morbidity. However, despite the clinical relevance of these infections, no data  
30 are available on differential outcomes in patients with first and second-hit infections  
31 depending on the nature of the causative organism. This study aims to explore any  
32 differences in these subgroups.

33 **Design.** In a retrospective, observational cohort study, the United Kingdom Intensive  
34 Care National Audit and Research Centre (ICNARC) database was used to explore the  
35 outcomes of patient with first-hit infections leading to sepsis, and sepsis patients with  
36 second-hit infections grouped according to the Gram status of the causative organism.

37 **Setting.** General critical care units in England, Wales, and Northern Ireland  
38 participating in the ICNARC programme between 1 January 2007 – 30 June 2012.

39 **Patients.** Patient groups analysed included 2119 patients with and 1319 patients without  
40 sepsis who developed an intensive care unit acquired infection in blood. Subgroups  
41 included patients with trauma, emergency neurosurgical, elective surgical, and  
42 cardiogenic shock.

43 **Measurements and main results.** Gram-negative organisms were associated with  
44 poorer outcomes in first-hit infections. The 90-day mortality of patients who developed  
45 a Gram-negative infection was 43.6% following elective surgery and 27.9% following  
46 trauma. This compared with a mortality of 25.6% and 20.6%, respectively, in Gram-  
47 positive infections. Unexpectedly, an inverse relationship between Gram status and  
48 mortality was observed in second-hit infections. Patients with an initial diagnosis of

49 sepsis who developed secondary infections caused by Gram-negative organisms had a  
50 90-day mortality of 40.4%, compared with 43.6% in Gram-positive infections.

51 **Conclusions.** Our study identifies a fundamental difference in patient outcomes  
52 between first-hit and second-hit bacterial infections, which may be due to genetic,  
53 microbiological, immunological, and environmental factors. This finding has direct  
54 implications for risk stratification and defines future research priorities.

55

56 Keywords: sepsis, bacterial infections, intensive care, Gram-positive bacterial  
57 infections, Gram-negative bacterial infections.

58

59

Provisional

## 60 **Introduction**

61 Measured using any chosen metric, sepsis is a devastating condition for patients,  
62 their families, and society as a whole (1,2). It accounts for 15-20% of all deaths in the  
63 developing world and kills over 1.5 million newborns and children every year (1,3). As  
64 a medical condition, it is more deadly than stroke, killing a third of all patients with the  
65 severe form of the illness (3,4). It is responsible for a third of admissions to the  
66 intensive care unit (ICU) and costs the economy of the United States alone \$17 billion  
67 annually (4-6). For patients who do survive, many carry a substantial burden of  
68 continued physical and psychological ill health, with return to work rates below 65%  
69 (5,7).

70 Large-scale surveillance studies have identified the most common organisms  
71 implicated in sepsis (8,9). Although fungal and viral infections contribute to many  
72 sepsis deaths, bacterial pathogens are the most frequent causative agents, with  
73 *Staphylococcus aureus* and *Streptococcus pneumoniae* representing the most relevant  
74 Gram-positive species, and *Escherichia coli*, *Klebsiella spp.*, and *Pseudomonas*  
75 *aeruginosa* dominating the Gram-negative group (4,9). The relative contribution by  
76 each of these different organism types is heavily influenced by local population  
77 characteristics, organism virulence, and health care structure variables.

78 The organism class responsible for the primary infection, has been shown to  
79 play a role in determining the mortality of patients with sepsis. In this study, these  
80 primary infections are termed “first-hit” infections. However, there are conflicting  
81 findings regarding the magnitude and the direction of the differences between Gram-  
82 positive and Gram-negative infections (10-12). The largest of these studies (12), with  
83 over 5 million patient records in the United States analysed retrospectively, attributed a

84 mortality of 30.4% to sepsis caused by Gram-positive organisms and 23.3% to Gram-  
85 negative organisms. However, the highest mortality in this cohort was 36.3% in patients  
86 infected with anaerobic Gram-negative microbes suggesting the importance of further  
87 stratification according to organism types instead of solely relying on Gram status.

88         With improving rates of initial survival in severe sepsis (13-15), infections that  
89 occur following resolution of the initial insult carry an increasing burden of morbidity  
90 (13,15,16). In this study these infections are termed second-hit infections as opposed to  
91 first-hit infections that occur in patient's without prior sepsis. Many low virulence  
92 nosocomial infections occur following resolution of the initial primary infective insult  
93 and include pathologies such as ventilator-associated pneumonia, intravascular line  
94 infections as well as reactivation of latent chronic viral infections such as  
95 cytomegalovirus (9). However, despite the clinical relevance of these infections, there  
96 are no data available in the literature on differential outcomes from Gram-positive  
97 pathogens compared with Gram-negative species in patients with first and second-hit  
98 infections. We here attempted to address this knowledge gap, using both local data from  
99 a single hospital and data from a national audit database in the United Kingdom.

## 100 **Materials and Methods**

101         The design, management, and analysis of this observational cohort study were  
102 conducted according to the principles declared in The World Medical Association's  
103 Declaration of Helsinki. All data were analysed anonymously, retrospectively, and did  
104 not impact upon the clinical care of any patients.

105         The definitions of sepsis and systemic inflammatory response syndrome (SIRS)  
106 were based on the 2012 Surviving Sepsis Guidelines in place at that time (17). The local

107 data collection was approved by the South East Wales Research Ethics Committee  
108 (reference number 10WSE/421, June 2011) and registered with the UK Clinical  
109 Research Network (UKCRN; Cellular and biochemical investigations in sepsis, ID  
110 11231).

111 The national data were screened from all admissions to NHS adult, general  
112 critical care units in England, Wales, and Northern Ireland participating in the Case Mix  
113 Programme of the Intensive Care National Audit & Research Centre (ICNARC) Data  
114 Specification between 1 January 2007 – 30 June 2012. An analysis plan was agreed *a*  
115 *priori* according to the following definitions:

116 **First-hit infection:** patients admitted with a non-infective diagnosis that  
117 subsequently developed an intensive care unit-acquired infection in blood.

118 **Second-hit infection:** patients admitted with severe sepsis as an initial diagnosis  
119 that subsequently developed an intensive care unit-acquired infection in blood.

120 All patients were categorised into those that developed Gram-positive or Gram-  
121 negative infection subtypes. Four specific patient subgroups were chosen before  
122 analysis as the first-hit cohort. These sub-groups were patients categorised as having  
123 trauma, emergency neurosurgical, elective surgical, and cardiogenic shock as their  
124 primary reason for intensive care admission. It has been shown that these patients can  
125 provide a plausible and accessible model of the development of severe sepsis (18).

126 As described above, patients in the second-hit cohort were admitted to the ICU  
127 with an initial diagnosis of severe sepsis, and then subsequently developed an intensive  
128 care unit-acquired infection in blood. Thereafter, the same descriptive statistics and  
129 survival analyses were applied to patients with first-hit and second-hit infections. Acute



130 hospital mortality was defined as the status at ultimate discharge from the acute  
131 hospital, excluding re-admissions within the same hospital stay.

132         The main organism causing the first-hit infection in blood was defined as the  
133 presence of an infection in any blood sample taken for microbiological culture 48 hours  
134 or more following admission to the intensive care unit. Similarly, second-hit infection in  
135 blood was defined as the presence of infective bacteria in any blood sample taken for  
136 microbiological culture 48 hours or more following admission to the intensive care unit  
137 in patients admitted with severe sepsis as initial diagnosis. If two organisms were  
138 isolated in both blood culture bottles, first organism priority was given according to the  
139 following ranking used by ICNARC: Methicillin resistant *Staphylococcus aureus*  
140 (MRSA); *Staphylococcus aureus* (not MRSA); vancomycin resistant *Enterococcus spp.*  
141 (VRE); *Enterococcus spp.* (not VRE); yeast (e.g. *Candida spp.*); *Pseudomonas spp.*;  
142 *Acinetobacter spp.*; *Enterobacter spp.*; *Klebsiella spp.*; *Serratia spp.*; *Escherichia coli*;  
143 or other organisms entered using free text. The Gram classifications were then specified  
144 from the organism reported as the main organism causing first unit-acquired infection in  
145 blood.

146         The local dataset consisted of patients admitted with severe sepsis to the  
147 intensive care unit (ICU) at The Royal Glamorgan Hospital, Llantrisant, UK between  
148 2010 and 2013 were retrospectively analysed for 90-day all-cause mortality according  
149 to the Gram status of the organism responsible for their initial sepsis diagnosis. Due to  
150 the narrow limits of this data collection restricted to electronically captured  
151 microbiological data and outcome data only, it was not possible to propensity match  
152 patients nor compare other cofounders such as age that may lead to excessive mortality  
153 in one arm of this study.

154 Cumulative survival curves as a function of time were generated using the  
155 Kaplan-Meier approach with censored results indicating patient discharge and compared  
156 using the log-rank test. Intergroup differences in baseline characteristics were compared  
157 using a two-Way ANOVA, unmatched and corrected for multiple comparisons with a  
158 Sidak test using SPSS 20.0.

159 The funders had no role in study design, data collection, data analysis, data  
160 interpretation, or writing of the report. All authors had full access to all the data in the  
161 study and share final responsibility for the decision to submit for publication. The  
162 ICNARC data is available on request directly to [icnarc@icnarc.org](mailto:icnarc@icnarc.org).

## 163 **Results**

### 164 *Outcomes from first-hit infections according to local and national datasets*

165 The Kaplan-Meier curve shown in Figure 1A demonstrates that when a Gram-  
166 negative organism was identified as the prime cause of sepsis, patients had an excessive  
167 mortality rate of 29.1% compared with 21.3% for those where a Gram-positive  
168 organism was identified. This was equivalent to an odds ratio for death of 1.8 (1.18 –  
169 2.73) in the Gram-negative subgroup.

170 In order to corroborate this relationship on a national scale, ICNARC's database  
171 of UK critical care units was used. ICNARC records do not include the causative  
172 organisms responsible for admissions to ICU with severe sepsis. The only recorded  
173 organism names are those responsible for "unit-acquired infections" occurring within 72  
174 hours following admission to ICU with alternative pathologies. We therefore identified  
175 groups of patients admitted to ICU without an infective aetiology (trauma and elective  
176 surgery patients) to examine clinical outcome differences following acquisition of a

177 unit-acquired infection that could act as a surrogate for first-hit infection causing severe  
178 sepsis.

179 The baseline characteristics of these groups of first-hit patients are shown in  
180 Table 1. While intergroup differences existed between trauma and elective surgery  
181 patients, as expected, the Gram-positive and Gram-negative groups within each cohort  
182 showed no significant differences in baseline parameters. Despite this similarity in  
183 morbidity, mortality rates showed striking differences between the two groups.  
184 Importantly, the mortality patterns in trauma (Fig.1B) and elective surgery patients  
185 (Fig.1C) matched that of the local dataset (Fig.1A). Mortality from Gram-negative  
186 infections in the trauma and elective groups was 27.9% and 43.6%, respectively,  
187 compared with 20.6% and 25.6% for Gram-positive infections. Overall, this translated  
188 to an odds ratio for death of 1.4 and 1.7, respectively, in trauma and elective surgery  
189 patients with Gram-negative infections. No significant differences were found in the  
190 mortality of patients with cardiogenic shock and those undergoing emergency  
191 neurosurgery although the numbers in these sub-groups were low. (Suppl. Fig.1).

#### 192 ***National outcomes from second-hit infections***

193 As ICNARC records unit-acquired organism names in different cohorts of  
194 patient groups, it was possible to examine the mortality in severe sepsis patients who  
195 develop a second-hit infection. The baseline characteristics of these patients had no  
196 statistical differences when using Gram status as a comparator (Table 1). However,  
197 compared with first-hit infections, an inverse relationship between Gram status and  
198 mortality was seen. Second-hit infections in sepsis patients had a mortality of 40.4%  
199 when a Gram-negative infection was responsible compared with 43.6% when Gram-

200 positive organisms were recorded (Fig.1D). This resulted in an odds ratio for death of  
201 0.8 following infection with Gram-negative pathogens in second-hit infections.

202

### 203 **Discussion**

204 The present analysis accords with previous studies showing that first-hit  
205 infections caused by Gram-negative organisms result in a greater mortality in sepsis  
206 compared with Gram-positive pathogens (12). In striking contrast to this pattern in  
207 primary infections, our findings are the first to show that Gram-positive second-hit  
208 infections carry a higher risk of death compared to infections caused by Gram-negative  
209 pathogens. Of note, the national scale and standardised reporting of the corresponding  
210 data provide a significant advance in the analysis of differential outcomes in well-  
211 defined subgroups of patients developing first-hit or second-hit sepsis, that can now be  
212 addressed further in the clinic and experimentally.

213 Although infection-related organ dysfunction continues to be responsible for  
214 approximately 30% of ICU admissions, there is a surprising lack of comparative  
215 epidemiological data on the recent trends of infective organisms. The largest such  
216 dataset to-date, the EPIC II study, is almost 10 years old (11). In that study, the  
217 investigators found a larger prevalence of Gram-negative infections and worse  
218 outcomes associated with certain organisms, and observed a significant relationship  
219 between time spent on the ICU and development of infections, particularly those caused  
220 by methicillin-resistant *S. aureus* (MRSA), *Acinetobacter* and *Pseudomonas* species  
221 (11). A small-scale study from mainland China recently confirmed this distribution of  
222 the infective organisms (16). Our present findings demonstrate that the relative risk

223 attributable to Gram-negative compared with Gram-positive mortality may be as high as  
224 1.7 for first-hit infections.

225         The underlying causes for these mortality differences are likely to be  
226 multifactorial. Firstly, there may be logistical and procedural reasons as to why these  
227 patients have an excessive mortality. The increasing levels of multidrug-resistant Gram-  
228 negative organisms (17,18) may render patients with these causative organisms more  
229 likely to receive ineffective initial therapy (19,20). However, recent data from the  
230 World Healthcare-Associated Infections Forum indicates that multidrug-resistant Gram-  
231 negative organisms only play a very small role in the UK with incidences below 5%,  
232 making this explanation less plausible (21).

233         Secondly, there may be unmeasured pathological differences due to the  
234 epidemiology of different organisms. In fact, after adjustments for organism class and  
235 type, the site of infection appears to play a key role in differential patient survival  
236 (10,21,22). With the knowledge that patterns of microbial classes differ between  
237 different infectious sources, simply basing a mortality prediction on an organism type  
238 may act as a surrogate for the likely source of infection. This may help explain some of  
239 the variation shown in the literature comparing organism class and species. The extent  
240 of variation shown in those studies exposes many of the difficulties inherent in  
241 retrospective analysis of a syndrome characterised by a number of individual disease  
242 entities across a hugely variable cohort of patients. In conjunction with widely varying  
243 microbial resistance patterns across different countries, the inconsistent use and timing  
244 of appropriate antibiotics makes comparing international results a difficult task and  
245 further highlights the need for better quality data.

246 Thirdly, the differences in outcome between Gram-negative and Gram-positive  
247 infections may represent a particular predisposition of different patients to develop  
248 distinct types of infections (16,23-26). What has been observed in our study may simply  
249 be an excessive mortality due to genetic and environmental differences rather than the  
250 microorganisms directly. However, despite these possibilities, it is undeniable that the  
251 Gram status can be used as a strong signal to point towards an expected excessive  
252 mortality. This in itself is important and useful.

253 Finally, there are clear immunological differences that occur as a result of an  
254 organism's structural and biochemical characteristics. As a classical example, this may  
255 predominantly be due to the presence of a lipopolysaccharide (LPS)-containing cell wall  
256 in Gram-negative bacteria. LPS is recognised by a range of cell types and promotes  
257 inflammation as well as acts as potent inducer of the coagulation cascade (27). In  
258 addition to the presence of LPS as a major discriminator between Gram-negative and  
259 Gram-positive bacteria, such mortality differences seen here may also be influenced by  
260 other pathogen-specific characteristics including the ability of most Gram-negative  
261 organisms to activate innate-like V $\gamma$ 9/V $\delta$ 2 T cells and mucosal-associated invariant T  
262 (MAIT) cells (28,29). Individual organism pathogenicity will also influence patient  
263 outcomes as much as the pharmacokinetics of the drugs used to target such microbes.  
264 Therefore, more virulent Gram-negative microbes may more rapidly replicate and have  
265 higher toxin loads (30).

266 What is more intriguing than the relationship between Gram status and mortality  
267 from first-hit infection is the apparent inverse relationship between mortality and Gram  
268 status in sepsis patients who subsequently acquire a second-hit infection. Again, this is  
269 likely to be multifactorial. There is a wealth of immunological literature demonstrating

270 profound reprogramming effects on both cellular and humoral immunity that severe  
271 sepsis leaves in its wake (23-26,28,31,32). These tolerising effects may render survivors  
272 of first-hit infections more resistant to subsequent Gram-negative sepsis. There may  
273 also be organisational aspects to these mortality differences including the use of  
274 antimicrobials with adverse side effect profiles in Gram-positive second-hit infections  
275 to cover the possibility of MRSA infection. Furthermore, there may be a survival bias to  
276 these data. For example, those patients who survive an initial Gram-negative infection  
277 may have an inherent resistance to Gram-negative infections. Therefore, these patients  
278 may be more likely to survive and subsequently develop second-hit infections, and the  
279 data might thus be skewed towards a survival benefit of Gram-negative infection when  
280 these patients develop a second infection.

281 Several improvements could be made in future studies of this topic. Firstly,  
282 microbiological data on true first-hit sepsis patients were not available through  
283 ICNARC's dataset. Therefore, we defined surrogate first-hit infection subgroups  
284 including post-operative elective surgery and trauma patients. There is a large volume  
285 of research supporting the use of these groups of patient's as a model for investigating  
286 first-hit infection(18). With the advent of new nation-wide systems of sepsis outcomes  
287 such as the recording through the work of the UK Sepsis Trust and the National Institute  
288 for Health and Care Excellence (NICE), causative organism data may be possible to  
289 analyse in the future. Indeed, new trial design may be a key component of improving  
290 research in this area (3). Studies should also aim to address the survival bias discussed  
291 above. By recording the initial infecting organism responsible for the first-hit sepsis, it  
292 should be possible to explore such relationships further.

293 Secondly, although the ICNARC dataset has considerable power due to its size  
294 and robust collection methods, it suffers from lack of granular detail and a relatively  
295 arbitrary collection priority of organisms. It would be important in future research to  
296 record when and from where individual organisms are isolated. The ranking of  
297 organisms allowing only a single species to be recorded may bias data collection in  
298 favour of Gram-positive infections that in turn may skew future analysis. The list of  
299 organisms was based on data from the European Centre for Disease Prevention and  
300 Control for the UK and has been shown to be representative in independent datasets  
301 (33). Therefore, ICNARC outcome data have significant clinical relevance in everyday  
302 practice. In addition to these possible confounders, the disease severity scores in the  
303 present study were recorded at the time of ICU admission, rather than at the time of  
304 initial pathology (i.e. surgical procedure time point), and may thus have diverged by the  
305 time of subsequent ICU admission. Unfortunately, the ICNARC dataset is not able to  
306 compensate for these factors. However, despite these methodical issues, they remain  
307 constant in all groups studied and as such cannot account for the reversal of mortality in  
308 first-hit compared with second-hit infections. This is a clear signal being sent although  
309 the intricacies of this detail will need to be addressed with a different future  
310 methodology.

### 311 **Conclusion**

312 Overall, our study demonstrates that Gram-negative infections are associated with a  
313 greatly elevated mortality in first-hit sepsis patients whilst these differences are reversed  
314 in second-hit infections. These findings will allow clinicians to better plan and deliver  
315 care to the patients most at risk from severe sepsis by targeting resources more  
316 effectively. It may also form a platform to explore the immune reprogramming effects



317 of sepsis *ex vivo* by comparing subsequent responses from patients with differing initial  
318 infection types.

319 **Acknowledgements**

320 The work described received support from the UK Clinical Research Network Study  
321 Portfolio, SARTRE/SEWAHSP Health Technology Challenge Scheme and MRC  
322 Confidence in Concept scheme. TS was in receipt of a Clinical Research Fellowship  
323 from the National Institute of Social and Health Care Research (NISCHR).

Provisional

## References

1. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in children. *The Lancet*. 2005 Mar;365(9465):1147–52.
2. Newton S, Cunningham J, Dobbin J. Sepsis and the NHS. All-Party Parliamentary Group on Sepsis.
3. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two Decades of Mortality Trends Among Patients With Severe Sepsis. *Critical Care Medicine*. 2014 Mar;42(3):625–31.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Critical Care Medicine*. 2001 Jul;29(7):1303–10.
5. Schmid A, Burchardi H, Clouth J, Schneider H. Burden of illness imposed by severe sepsis in Germany. *Eur J Health Econ*. 2002;3(2):77–82.
6. Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day AG. A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care. *Crit Care*. 2007;11(6):R128.
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. pp. 1644–55.
8. Opal SM, Cohen J. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? *Critical Care Medicine*. 1999 Aug;27(8):1608–16.
9. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*. 2009 Dec 2;302(21):2323–9.
10. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. *Critical Care Medicine*. 2006 Feb;34(2):344–53.
11. Labelle A, Juang P, Reichley R, Micek S, Hoffmann J, Hoban A, et al. The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment. *Critical Care Medicine*. 2012 Jul;40(7):2016–21.
12. Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB. Variations in organism-specific severe sepsis mortality in the United States: 1999-2008. *Critical Care Medicine*. 2015 Jan;43(1):65–77.

13. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. *Critical Care Medicine*. 2010 Apr;38(4):1045–53.
14. McPherson D, Griffiths C, Williams M, Baker A, Klodawski E, Jacobson B, et al. Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010. *BMJ Open*. 2013;3(8).
15. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. *JAMA*. 1995 Aug;274(8):639–44.
16. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. Human Toll-Like Receptor 4 Mutations but Not CD14 Polymorphisms Are Associated with an Increased Risk of Gram-Negative Infections. *Journal of Infectious Diseases*. 2002 Nov 15;186(10):1522–5.
17. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. 2013. pp. 580–637.
18. Cain DJ, del Arroyo AG, Ackland GL. Man is the new mouse: Elective surgery as a key translational model for multi-organ dysfunction and sepsis. *Journal of the Intensive Care Society*. 2015 May 1;16(2):154–63.
19. Micek S, Johnson MT, Reichley R, Kollef MH. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. *BMC Infect Dis*. 2012;12:56.
20. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. *Crit Care*. 2014;18(6):596.
21. Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A. Association between Source of Infection and Hospital Mortality in Patients Who Have Septic Shock. *American Journal of Respiratory and Critical Care Medicine*. 2014 May 15;189(10):1204–13.
22. De Waele J, Lipman J, Sakr Y, Marshall JC, Vanhems P, Barrera Groba C, et al. Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. *BMC Infect Dis*. 2014;14:420.
23. Cavillon J-M, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. *Crit Care*. 2006;10(5):233.
24. Escoll P, del Fresno C, García L, Vallés G, Lendínez MJ, Arnalich F, et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients.

- Biochemical and Biophysical Research Communications. 2003  
Nov;311(2):465–72.
25. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor  $\kappa$ B. *Proceedings of the National Academy of Sciences. National Acad Sciences*; 2009;106(35):14978–83.
  26. Lynn LA. The diagnosis of sepsis revisited - a challenge for young medical scientists in the 21st century. *Patient Saf Surg*. 2014;8(1):1.
  27. Mansur A, Gruben von L, Popov AF, Steinau M, Bergmann I, Ross D, et al. The regulatory toll-like receptor 4 genetic polymorphism rs11536889 is associated with renal, coagulation and hepatic organ failure in sepsis patients. *J Transl Med*. 2014;12:177.
  28. Davey MS, Morgan MP, Liuzzi AR, Tyler CJ, Khan MWA, Szakmany T, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. *The Journal of Immunology*. 2014 Oct 1;193(7):3704–16.
  29. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaz F, et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. *Intensive Care Med*. 2014 Feb;40(2):192–201.
  30. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. *virulence*. 2014 Jan 1;5(1):213–8.
  31. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. *Nat Rev Drug Discov*. 2007 Apr;6(4):287–93.
  32. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *The Lancet Infectious Diseases*. 2013 Mar;13(3):260–8.

## **Contributors**

MM, KR and ME designed the study. TS and PO abstracted the local data. SP and KR abstracted the national data from the Case Mix Programme. MM, SP and KR directed and conducted the data analysis. MM, TS and ME wrote the paper. JH provided expert advice and revised the draft. All authors read and approved the final version.

## **Funding**

Dr. Szakmany reports grants from National Institute of Social and Health Care Research, Welsh Assembly Government, UK, during the conduct of the study.

Dr Eberl reports grants from SARTRE/SEWAHSP Health Technology Challenge and the MRC Confidence in Concept scheme, during the conduct of the study.

Provisional

**Table 1 Baseline patient characteristics from the ICNARC dataset according to infecting organism type.**

	First-hit (trauma)		First-hit (elective surgery)		Second-hit	
	<i>Gram +</i>	<i>Gram -</i>	<i>Gram +</i>	<i>Gram -</i>	<i>Gram +</i>	<i>Gram -</i>
<b>Number of admissions % [N]</b>	49.8 [353]	49.4 [350]	46.4 [308]	53.2 [308]	47.3 [1,009]	52.1 [1,110]
<b>Age mean (sd)</b>	48.6 (20.0)	49.5 (19.8)	64.4 (14.6)	67.6 (12.8)	61.9 (14.9)	61.6 (15.4)
<b>Gender % male</b>	77.9	74.9	69.2	76.8	60.5	59.4
<b>Caucasian %</b>	88.6	90.6	95.6	96.9	94.0	92.4
<b>Liver condition in PMH %</b>	1.1	1.1	2.0	4.0	48.6	47.8
<b>Renal condition in PMH %</b>	0.0	1.7	0.0	2.0	1.7	1.6
<b>Respiratory condition in PMH %</b>	0.6	0.6	1.0	4.0	48.4	47.5
<b>Cardiovascular condition in PMH %</b>	0.3	0.3	2.0	4.0	0.9	0.8
<b>In- hospital CPR %</b>	0.8	4.0	2.0	3.0	3.1	2.3
<b>Community CPR %</b>	0.0	2.0	0.0	0.0	0.3	0.4
<b>No CPR %</b>	97.2	94.0	98.3	97.9	96.6	97.3
<b>ICNARC mean (sd)</b>	19.4 (6.7)	20.9 (7.2)	18.2 (8.3)	17.8 (7.3)	25.2 (8.1)	25.5 (8.1)
<b>APACHE II mean (sd)</b>	14.5 (6.2)	14.9 (6.7)	16.5 (5.8)	16.2 (4.7)	20.4 (6.3)	20.3 (6.5)
<b>Acute hospital mortality %</b>	20.6	27.9 **	25.6	43.6 **	46.3	40.4 **

There were no significant differences in these baseline characteristics between organism types within respective groups to explain the mortality differences observed by Gram-status. The results were analysed using a Two-Way ANOVA, unmatched

and corrected for multiple comparisons with a Sidak test.  $p < 0.05$  \*,  $p < 0.01$  \*\*,  $p < 0.001$  \*\*\*. PMH, past medical history; CPR, cardiopulmonary resuscitation; APACHE, Acute Physiology And Chronic Health Evaluation.

**Figure 1. Kaplan-Meier analysis of sepsis patient survival according to Gram status of the causative organism.** (A) Local dataset of first-hit sepsis patients (n=350). (B) ICNARC dataset of first-hit trauma patients developing a unit-acquired infection (n=703). (C) ICNARC dataset of first-hit elective surgery patients developing a unit-acquired infection (n=616). (D) ICNARC dataset of second-hit sepsis patients subsequently developing a unit-acquired infection (n=2131). All Gram differences are significant using the Mantel-Cox (Log-rank) test at  $p < 0.01$ .

**Supplementary figure. Kaplan-Meier analysis of sepsis patient survival according to Gram status of the causative organism.** (A) ICNARC dataset of first-hit emergency neurosurgical patients developing a unit-acquired infection (n=104). (B) ICNARC dataset of first-hit cardiogenic shock patients developing a unit-acquired infection (n=56). None of the Gram differences are significant using the Mantel-Cox (Log-rank) test at  $p < 0.05$ .

Figure 1.TIFF

